Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05710315
NA

Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

Sponsor: Inova Health Care Services

View on ClinicalTrials.gov

Summary

The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion. RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in patients 5 years of age or older. While the use of RELiZORB™ in this study is consistent with the FDA approval, the use of RELiZORB™ in patients with multi organ failure is not in the current standard of care practice at Inova Health Care facilities.

Official title: Single-center, Proof of Concept, Prospective Study Evaluating the Utility of RELiZORB™ for the Treatment of Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure

Key Details

Gender

All

Age Range

18 Years - 89 Years

Study Type

INTERVENTIONAL

Enrollment

32

Start Date

2025-05-07

Completion Date

2026-05-31

Last Updated

2026-02-04

Healthy Volunteers

No

Interventions

DEVICE

RELiZORB™

RELiZORB cartridges will be used with routine enteral feedings for 5 days for randomized participants

OTHER

Placebo

Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants

Locations (1)

Inova Fairfax Medical Campus

Falls Church, Virginia, United States